Adjuvants for Enhancing the Immunogenicity of Whole Tumor Cell Vaccines
- 10 May 2011
- journal article
- review article
- Published by Taylor & Francis in International Reviews of Immunology
- Vol. 30 (2-3) , 150-182
Abstract
Whole tumor cell lysates can serve as excellent multivalent vaccines for priming tumor-specific CD8+ and CD4+ T cells. Whole cell vaccines can be prepared with hypochlorous acid oxidation, UVB-irradiation and repeat cycles of freeze and thaw. One major obstacle to successful immunotherapy is breaking self-tolerance to tumor antigens. Clinically approved adjuvants, including Montanide™ ISA-51 and 720, and keyhole-limpet proteins can be used to enhance tumor cell immunogenicity by stimulating both humoral and cellular anti-tumor responses. Other potential adjuvants, such as Toll-like receptor agonists (e.g., CpG, MPLA and PolyI:C), and cytokines (e.g., granulocyte-macrophage colony stimulating factor), have also been investigated.Keywords
This publication has 196 references indexed in Scilit:
- Whole tumor antigen vaccinesSeminars in Immunology, 2010
- Hierarchy of immunosuppressive strength among myeloid‐derived suppressor cell subsets is determined by GM‐CSFEuropean Journal of Immunology, 2009
- Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapyNature Medicine, 2007
- Intratumoural injection of the toll-like receptor-2/6 agonist ‘macrophage-activating lipopeptide-2’ in patients with pancreatic carcinoma: a phase I/II trialBritish Journal of Cancer, 2007
- Adjuvant-enhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challengesVaccine, 2007
- Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patientsCancer Immunology, Immunotherapy, 2006
- Toll-like receptor signallingNature Reviews Immunology, 2004
- Molecular identification of a danger signal that alerts the immune system to dying cellsNature, 2003
- Hydrogen peroxide as second messenger in lymphocyte activationNature Immunology, 2002
- A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activationEuropean Journal of Immunology, 1995